Hepatic gluconeogenesis and peripheral insulin sensitivity pathways

Hepatic gluconeogenesis and peripheral insulin sensitivity pathways are the primary physiological systems governing blood glucose regulation. Hepatic gluconeogenesis involves the synthesis of glucose from non-carbohydrate precursors such as lactate and glycerol, a process primarily controlled by the liver to maintain blood sugar during fasting [StatPearls: NBK534877]. Peripheral insulin sensitivity refers to the ability of muscle and adipose tissues to effectively take up glucose in response to insulin signaling, primarily through the translocation of GLUT4 transporters to the cell membrane [PubMed: 29994730]. In conditions like Type 2 Diabetes Mellitus, these pathways are severely impaired, characterized by excessive hepatic glucose output and reduced peripheral glucose disposal. Pharmacological agents like Metformin target these pathways by inhibiting mitochondrial complex I and activating AMPK to reduce gluconeogenesis, while Thiazolidinediones act as PPAR-gamma agonists to enhance insulin sensitivity in peripheral tissues [PubMed: 23147070, PubMed: 25183118]. Understanding the interplay between these pathways is crucial for developing comprehensive treatments for metabolic syndrome and related cardiovascular complications.

Other names

Glucose metabolism pathwaysInsulin signaling and glucose production pathwaysHepatic glucose output and peripheral glucose uptake systems

Metformin suppresses hepatic gluconeogenesis by inhibiting mitochondrial complex I and activating AMPK; Thiazolidinediones (TZDs) improve peripheral insulin sensitivity by activating the nuclear receptor PPAR-gamma [PubMed: 23147070, PubMed: 25183118].